Zydus Ties Up With Synthon for MS Drug in US
ECONOMY & POLICY

Zydus Ties Up With Synthon for MS Drug in US

Zydus Lifesciences Ltd announced on Thursday that its subsidiary has signed an exclusive licensing and supply agreement with Netherlands-based Synthon BV to introduce a generic version of Ozanimod capsules in the United States for the treatment of relapsing forms of multiple sclerosis (MS).
The drug is the generic equivalent of ZEPOSIA, a therapy used in managing various relapsing MS conditions. The agreement was disclosed through a regulatory filing.
As per the arrangement, Synthon BV will take on the responsibility for securing final regulatory approval from the US Food and Drug Administration (FDA), followed by the manufacture and supply of the capsules. Zydus, through its US subsidiary, will oversee commercialisation across the American market.
“This collaboration with Synthon enables us to bring this important treatment to the US market,” said Punit Patel, President and CEO of Zydus Pharmaceuticals (USA) Inc.
The total addressable market for Ozanimod capsules in the US is estimated at USD 637 million (approximately Rs 53.1 billion), according to IQVIA MAT data as of July 2025.
This strategic move strengthens Zydus Lifesciences’ presence in the neurology space and further expands its portfolio of complex generics in the US pharmaceutical market. 

Zydus Lifesciences Ltd announced on Thursday that its subsidiary has signed an exclusive licensing and supply agreement with Netherlands-based Synthon BV to introduce a generic version of Ozanimod capsules in the United States for the treatment of relapsing forms of multiple sclerosis (MS).The drug is the generic equivalent of ZEPOSIA, a therapy used in managing various relapsing MS conditions. The agreement was disclosed through a regulatory filing.As per the arrangement, Synthon BV will take on the responsibility for securing final regulatory approval from the US Food and Drug Administration (FDA), followed by the manufacture and supply of the capsules. Zydus, through its US subsidiary, will oversee commercialisation across the American market.“This collaboration with Synthon enables us to bring this important treatment to the US market,” said Punit Patel, President and CEO of Zydus Pharmaceuticals (USA) Inc.The total addressable market for Ozanimod capsules in the US is estimated at USD 637 million (approximately Rs 53.1 billion), according to IQVIA MAT data as of July 2025.This strategic move strengthens Zydus Lifesciences’ presence in the neurology space and further expands its portfolio of complex generics in the US pharmaceutical market. 

Related Stories

Gold Stories

Next Story
Resources

Schindler named among Forbes’ World’s Best Employers 2026

Schindler has been named among Forbes’ World’s Best Employers 2026, a global ranking recognising companies for their workplace environments.Compiled by Forbes in partnership with Statista, the ranking is based on independent employee feedback, including whether employees would recommend their organisation to friends and family.The company said the recognition reflected its focus on creating a workplace where employees can develop their expertise and build careers. ..

Next Story
Infrastructure Urban

India needs an export-execution mindset: Vishesh Jain

Interview with Vishesh Jain, Founder & CEO, EximpleWhat gaps in India’s global trade ecosystem led you to build Eximple, and what problem did you see businesses struggling with most?Eximple came out of a problem that all three founders had seen from different choke points in the trade ecosystem. India has millions of MSMEs and manufacturers, and many of them can make products that are genuinely competitive on quality. Yet only a small fraction is able to build meaningful international businesses. In our experience, the gap is usually not manufacturing capability; it is the ability to exe..

Next Story
Building Material

Nuvoco reports 13.5% revenue growth in Q2 FY27

Nuvoco Vistas Corp. Ltd. reported consolidated revenue of Rs 27.9 billion for Q2 FY27, up 13.5% year on year. Cement sales volume rose 9% to 4.7 million tonnes (MMT), while EBITDA increased 11% to Rs 4.11 billion.The company said it began its cement operations in 2014 with a 2.3 MMT per annum (MMTPA) operation at Nimbol. It now aims to reach 35 MMTPA of cement capacity by FY28, nearly 15 times its initial capacity. Its portfolio spans cement, ready-mix concrete and modern building materials.On sustainability and cost efficiency, Nuvoco partnered with CleanMax for a 46.4 MW wind-solar hybrid re..

Advertisement

Subscribe to Our Newsletter

Get daily newsletters around different themes from Construction world.

STAY CONNECTED

Advertisement

SPECIAL OFFER
QR Code